CorAlert

CorAlert is developing an accurate, easy-to-use, noninvasive detection and monitoring device for diagnosing heart failure (HF) in real time.

The CorAlert Opportunity

The market seeks a low-cost, noninvasive solution for early detection and monitoring of patients suffering from HF.

The Unique Product

Left Ventricular End-Diastolic Pressure (LVEDP), the pressure in the left ventricle after it has filled with blood and before it contracts, is an accepted measure to identify patients suffering from HF. In nearly all people with HF, LVEDP is elevated. Unfortunately, measuring LVEDP involves an invasive procedure that is rarely performed today.

CorAlert is developing an accurate, easy-to-use, noninvasive device for early detection and monitoring of HF in real time. CorAlert’s device accurately estimates LVEDP based on analyzing central aortic pressure and measuring heartbeats. The system consists of the CorAlert smart pump placed on the upper arm, a sensor placed on the chest, and CorAlert’s proprietary software for accurate estimates and analysis of LVEDP.

The Company’s noninvasive method provides a full hemodynamic profile based on three critical measurements:

  1. LVEDP
  2. delta (Δ) Pressure/delta (Δ) Time (dP/dt): rate of pressure increase in the aorta directly following contraction and opening of the aortic valve
  3. Systemic Vascular Resistance (SVR): resistance that must be overcome to push blood through the circulatory system and to create blood flow

CorAlert represents a new approach in the practice of cardiology that will significantly improve patient healthcare and reduce hospital costs. Its unique solution has been validated in more than 50 patients at Johns Hopkins Hospital, followed by a study at Kaplan and Ziv Medical Centers in Israel.

Team

  • Amir Marmor, C0-founder and CEO: Extensive experience in medical device start-ups as software/algorithm engineer
  • Alon Marmor, M.D., Co-founder and CMO: Professor of Medicine and Cardiology Chair, Bar-Ilan University; former Head of Heart Institute, Director of Cardiology Ziv Medical Center, Safed, Israel
  • Gal Menaged, Chairman: Extensive experience in investment and business development in high tech; currently, CEO of Prodac Systems.

Status

Founded: September 2016
Stage: Technology development
Investor: The Trendlines Group

Background & Market

Heart failure (HF) occurs as the heart muscle weakens. As a result, the heart struggles to meet the body’s needs. This condition manifests itself in shortness of breath, fatigue, and sudden weight gain. In its early stages, HF often goes undetected. As HF progresses, however, it may cause pulmonary edema, hospitalization, or death. HF affects 26 million adults worldwide, with more than 5.7 million in the United States. Up to 42% of patients admitted to hospitals with HF die within five years.

Both the mortality rate and high cost of treating HF are due to the difficulty in assessing the patient’s condition in real time, which may result in misdiagnosis.

Video


CEO Amir Marmor is interviewed on ILTV.

Contact

Amir Marmor, CEO
+972.54.796.9927
amir@coralertmed.com

CorAlert

Font Resize
Contrast